{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T13:42:49Z","timestamp":1794490969172,"version":"4.9.1"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2023,1,23]],"date-time":"2023-01-23T00:00:00Z","timestamp":1674432000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,4]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Ceftolozane\/tazobactam, a cephalosporin-\u03b2-lactamase inhibitor combination, active against multidrug-resistant Gram-negative pathogens, is approved for treatment of adults with complicated urinary tract infections (cUTI). Safety and efficacy of ceftolozane\/tazobactam in pediatric participants with cUTI, including pyelonephritis, were assessed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>This phase 2 study (NCT03230838) compared ceftolozane\/tazobactam with meropenem for treatment of cUTI in participants from birth to &lt;18 years of age. The primary objective was safety and tolerability. Key secondary end points included clinical cure and per-participant microbiologic response rates at end of treatment (EOT) and test of cure (TOC) visits.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>The microbiologic modified intent-to-treat (mMITT) population included 95 participants (ceftolozane\/tazobactam, n = 71; meropenem, n = 24). The most common diagnosis and pathogen were pyelonephritis (ceftolozane\/tazobactam, 84.5%; meropenem, 79.2%) and <jats:italic toggle=\"yes\">Escherichia coli<\/jats:italic> (ceftolozane\/tazobactam, 74.6%; meropenem, 87.5%); 5.7% (ceftolozane\/tazobactam) and 4.8% (meropenem) of <jats:italic toggle=\"yes\">E. coli<\/jats:italic> isolates were extended-spectrum \u03b2-lactamase-producers. Rates of adverse events were similar between treatment groups (any: ceftolozane\/tazobactam, 59.0% vs. meropenem, 60.6%; drug-related: ceftolozane\/tazobactam, 14.0% vs. meropenem, 15.2%; serious: ceftolozane\/tazobactam, 3.0% vs. meropenem, 6.1%). Rates of clinical cure for ceftolozane\/tazobactam and meropenem at EOT were 94.4% and 100% and at TOC were 88.7% and 95.8%, respectively. Rates of microbiologic eradication for ceftolozane\/tazobactam and meropenem at EOT were 93.0% and 95.8%, and at TOC were 84.5% and 87.5%, respectively.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Ceftolozane\/tazobactam had a favorable safety profile in pediatric participants with cUTI; rates of clinical cure and microbiologic eradication were high and similar to meropenem. Ceftolozane\/tazobactam is a safe and effective new treatment option for children with cUTI, especially due to antibacterial-resistant Gram-negative pathogens.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/inf.0000000000003832","type":"journal-article","created":{"date-parts":[[2023,1,23]],"date-time":"2023-01-23T21:02:18Z","timestamp":1674507738000},"page":"292-298","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":30,"title":["Safety and Efficacy of Ceftolozane\/Tazobactam Versus Meropenem in Neonates and Children With Complicated Urinary Tract Infection, Including Pyelonephritis: A Phase 2, Randomized Clinical Trial"],"prefix":"10.1097","volume":"42","author":[{"given":"Emmanuel","family":"Roilides","sequence":"first","affiliation":[{"name":"Third Department of Pediatrics, Infectious Diseases Unit, School of Medicine, Aristotle University and Hippokration General Hospital, Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Negar","family":"Ashouri","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, CHOC Children\u2019s Hospital, Orange, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John S.","family":"Bradley","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of California San Diego School of Medicine and Rady Children\u2019s Hospital of San Diego, San Diego, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew G.","family":"Johnson","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc., Rahway, New Jersey."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Lonchar","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc., Rahway, New Jersey."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng-Hsiu","family":"Su","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc., Rahway, New Jersey."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer A.","family":"Huntington","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc., Rahway, New Jersey."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myra W.","family":"Popejoy","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc., Rahway, New Jersey."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mekki","family":"Bensaci","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc., Rahway, New Jersey."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carisa","family":"De Anda","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc., Rahway, New Jersey."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth G.","family":"Rhee","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc., Rahway, New Jersey."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Bruno","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc., Rahway, New Jersey."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,1,23]]},"reference":[{"key":"R2-20250614","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S0140-6736(21)02724-0","article-title":"Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis.","volume":"399","year":"2022","journal-title":"Lancet"},{"key":"R4-20250614","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1111\/ped.12842","article-title":"Causative pathogens and antibiotic resistance in children hospitalized for urinary tract infection.","volume":"58","author":"Ko\u00e7ak","year":"2016","journal-title":"Pediatr Int"},{"key":"R5-20250614","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1001\/archpedi.159.10.924","article-title":"Antibiotic resistance patterns in children hospitalized for urinary tract infections.","volume":"159","author":"Lutter","year":"2005","journal-title":"Arch Pediatr Adolesc Med"},{"key":"R6-20250614","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.jinf.2016.07.014","article-title":"Prevalence of ESBL-producing Enterobacteriaceae in paediatric urinary tract infections: a systematic review and meta-analysis.","volume":"73","author":"Flokas","year":"2016","journal-title":"J Infect"},{"key":"R7-20250614","first-page":"436","article-title":"Pyelonephritis in pediatric uropathic patients: differences from community-acquired ones and therapeutic protocol considerations. A 10-year single-center retrospective study.","volume":"8","author":"Parente","year":"2021","journal-title":"Children (Basel)"},{"key":"R8-20250614","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/j.ajic.2021.04.077","article-title":"International Nosocomial Infection Control Consortium (INICC) report, data summary of 45 countries for 2013-2018, Adult and Pediatric Units, Device-associated Module.","volume":"9","author":"Rosenthal","year":"2021","journal-title":"Am J Infect Control"},{"key":"R9-20250614","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1097\/INF.0b013e31815e4122","article-title":"Prevalence of urinary tract infection in childhood: a meta-analysis.","volume":"27","author":"Shaikh","year":"2008","journal-title":"Pediatr Infect Dis J"},{"key":"R10-20250614","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.1542\/peds.2015-0409","article-title":"Risk factors for recurrent urinary tract infection and renal scarring.","volume":"136","author":"Keren","year":"2015","journal-title":"Pediatrics"},{"key":"R11-20250614","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1097\/MPG.0000000000000599","article-title":"Urinary tract infection in infancy is a risk factor for chronic abdominal pain in childhood.","volume":"60","author":"Rosen","year":"2015","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"R12-20250614","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ajem.2016.09.060","article-title":"Bacteremic vs nonbacteremic urinary tract infection in children.","volume":"35","author":"Megged","year":"2017","journal-title":"Am J Emerg Med"},{"key":"R13-20250614","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1542\/peds.2010-0685","article-title":"Risk of renal scarring in children with a first urinary tract infection: a systematic review.","volume":"126","author":"Shaikh","year":"2010","journal-title":"Pediatrics"},{"key":"R14-20250614","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1093\/cid\/ciw243","article-title":"Ceftazidime\/avibactam and ceftolozane\/tazobactam: second-generation \u03b2-lactam\/\u03b2-lactamase inhibitor combinations.","volume":"63","author":"van Duin","year":"2016","journal-title":"Clin Infect Dis"},{"key":"R16-20250614","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(14)62220-0","article-title":"Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI).","volume":"385","author":"Wagenlehner","year":"2015","journal-title":"Lancet"},{"key":"R17-20250614","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1097\/INF.0000000000002170","article-title":"Pharmacokinetics and safety of single intravenous doses of ceftolozane\/tazobactam in children with proven or suspected gram-negative infection.","volume":"37","author":"Bradley","year":"2018","journal-title":"Pediatr Infect Dis J"},{"key":"R18-20250614","doi-asserted-by":"crossref","first-page":"e02578","DOI":"10.1128\/AAC.02578-18","article-title":"Ceftolozane-tazobactam population pharmacokinetics and dose selection for further clinical evaluation in pediatric patients with complicated urinary tract or complicated intra-abdominal infections.","volume":"63","author":"Larson","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"R19-20250614","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/sim.4780040211","article-title":"Comparative analysis of two rates.","volume":"4","author":"Miettinen","year":"1985","journal-title":"Stat Med"},{"key":"R20-20250614","doi-asserted-by":"crossref","first-page":"S668","DOI":"10.1093\/ofid\/ofab466.1347","article-title":"Safety and efficacy of ceftolozane\/tazobactam plus metronidazole versus meropenem in pediatric participants with complicated intra-abdominal infection: a phase 2, randomized clinical trial.","volume":"8","author":"Jackson","year":"2021","journal-title":"Open Forum Infect. Dis"},{"key":"R21-20250614","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1093\/jac\/dkw374","article-title":"Efficacy of ceftolozane\/tazobactam against urinary tract and intra-abdominal infections caused by ESBL-producing Escherichia coli and Klebsiella pneumoniae: a pooled analysis of Phase 3 clinical trials.","volume":"72","author":"Popejoy","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"R22-20250614","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1093\/jac\/dkw053","article-title":"Efficacy of ceftolozane\/tazobactam versus levofloxacin in the treatment of complicated urinary tract infections (cUTIs) caused by levofloxacin-resistant pathogens: results from the ASPECT-cUTI trial.","volume":"71","author":"Huntington","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"R23-20250614","doi-asserted-by":"crossref","first-page":"126142","DOI":"10.1155\/2014\/126142","article-title":"Bacterial pathogens and antimicrobial resistance patterns in pediatric urinary tract infections: a four-year surveillance study (2009-2012).","volume":"2014","author":"Mirsoleymani","year":"2014","journal-title":"Int J Pediatr"},{"key":"R24-20250614","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1097\/INF.0000000000002395","article-title":"Safety and efficacy of ceftazidime-avibactam in the treatment of children \u22653 months to <18 years with complicated urinary tract infection: results from a phase 2 randomized, controlled trial.","volume":"38","author":"Bradley","year":"2019","journal-title":"Pediatr Infect Dis J"},{"key":"R25-20250614","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3389\/fcimb.2015.00045","article-title":"Epidemiology and characteristics of urinary tract infections in children and adolescents.","volume":"5","author":"Hanna-Wakim","year":"2015","journal-title":"Front Cell Infect Microbiol"},{"key":"R26-20250614","doi-asserted-by":"crossref","first-page":"ofaa139","DOI":"10.1093\/ofid\/ofaa139","article-title":"Ceftolozane\/tazobactam for treatment of severe ESBL-producing Enterobacterales infections: a multicenter nationwide clinical experience (CEFTABUSE II Study).","volume":"7","author":"Bassetti","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"R27-20250614","doi-asserted-by":"crossref","first-page":"e01970","DOI":"10.1128\/AAC.01970-17","article-title":"Activity of ceftolozane-tazobactam against carbapenem-resistant, non-carbapenemase-producing Pseudomonas aeruginosa and associated resistance mechanisms.","volume":"62","author":"Wi","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"R28-20250614","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.jgar.2019.07.017","article-title":"Activity of ceftolozane-tazobactam and comparators against Pseudomonas aeruginosa from patients in different risk strata - SMART United States 2016-2017.","volume":"20","author":"Lob","year":"2020","journal-title":"J Glob Antimicrob Resist"},{"key":"R29-20250614","doi-asserted-by":"crossref","first-page":"2907","DOI":"10.1093\/jac\/dkaa278","article-title":"Susceptibility trends of ceftolozane\/tazobactam and comparators when tested against European Gram-negative bacterial surveillance isolates collected during 2012-18.","volume":"75","author":"Sader","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"R30-20250614","doi-asserted-by":"crossref","first-page":"e01045","DOI":"10.1128\/AAC.01045-17","article-title":"Antimicrobial activity of ceftazidime-avibactam tested against multidrug-resistant Enterobacteriaceae and Pseudomonas aeruginosa isolates from U.S. medical centers, 2013 to 2016.","volume":"61","author":"Sader","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"R31-20250614","doi-asserted-by":"crossref","first-page":"174","DOI":"10.3343\/alm.2017.37.2.174","article-title":"Susceptibility of ceftolozane-tazobactam and ceftazidime-avibactam against a collection of \u03b2-lactam-resistant gram-negative bacteria.","volume":"37","author":"Gonzalez","year":"2017","journal-title":"Ann Lab Med"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000003832","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,15]],"date-time":"2025-06-15T00:05:33Z","timestamp":1749945933000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000003832"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,23]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000003832","relation":{},"ISSN":["0891-3668"],"issn-type":[{"value":"0891-3668","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1,23]]}}}